Cessation of aspirin and continuation of P2Y12 inhibitor monotherapy rather than ongoing dual antiplatelet therapy (DAPT) may be warranted within months of coronary revascularisation. A meta-analysis of individual data from 23,308 patients in six RCTs compared P2Y12 inhibitor monotherapy versus DAPT following percutaneous or surgical revascularisation for stable or unstable coronary artery disease. Most patients ...
Paradigm shift: DAPT loses out to P2Y12 inhibitor monotherapy
By Mardi Chapman
21 Jun 2021